Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BPMC - Blueprint Medicines Corporation
Market Cap 3.28B P/E - EPS this Y 84.70% Ern Qtrly Grth -
Income -205.49M Forward P/E -7.34 EPS next Y - 50D Avg Chg -9.00%
Sales 362.8M PEG 0.79 EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 7.92 EPS next 5Y -92.01% 52W High Chg -32.00%
Recommedations 2.00 Quick Ratio 3.48 Shares Outstanding 63.35M 52W Low Chg 44.00%
Insider Own 0.93% ROA -19.26% Shares Float 62.65M Beta 0.58
Inst Own 106.43% ROE -65.09% Shares Shorted/Prior 3.67M/4.05M Price 54.30
Gross Margin 95.71% Profit Margin -56.64% Avg. Volume 721,614 Target Price 127.35
Oper. Margin -31.16% Earnings Date Oct 24 Volume 3,157,311 Change -15.34%
Healthcare | Biotechnology | United States
About Blueprint Medicines Corporation

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation News
12/18/24 Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/07/24 Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
12/02/24 Exploring Three High Growth Tech Stocks in the United States
11/29/24 Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
11/14/24 Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
11/02/24 Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
11/01/24 High Growth Tech Stocks to Watch in November 2024
11/01/24 Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations
10/31/24 BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
10/31/24 Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ...
10/30/24 Q3 2024 Blueprint Medicines Corp Earnings Call
10/30/24 Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
10/30/24 Blueprint Medicines: Q3 Earnings Snapshot
10/30/24 Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
10/27/24 Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic?
10/25/24 Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
10/24/24 Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
10/23/24 Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:00 AM Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock?
10/16/24 Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Albers Jeffrey W. Director Director Jan 25 Sell 82.3 25,000 2,057,500 176,050 01/29/24
Albers Jeffrey W. Director Director Jan 25 Option 8.44 25,000 211,000 201,050 01/29/24
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 22 Sell 90 714 64,260 14,324 12/26/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 22 Option 8.8 714 6,283 15,038 12/26/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 15 Sell 84.35 3,914 330,146 14,324 12/19/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Dec 15 Option 1.87 3,654 6,833 16,411 12/19/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 07 Sell 75 5,000 375,000 24,495 12/11/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 07 Option 54.13 5,000 270,650 29,495 12/11/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Dec 04 Sell 71.43 600 42,858 24,495 12/06/23
Albers Jeffrey W. Director Director Nov 24 Sell 67.53 15,000 1,012,950 176,050 11/28/23
Albers Jeffrey W. Director Director Nov 24 Option 1.87 15,000 28,050 191,050 11/28/23
Albers Jeffrey W. Director Director Nov 01 Option 36.05 10,000 360,500 177,535 11/03/23
Albers Jeffrey W. Director Director Nov 01 Sell 60.39 10,000 603,900 176,050 11/03/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Oct 26 Sell 56.40 600 33,840 25,095 10/30/23
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Oct 04 Sell 48.06 3,769 181,138 62,080 10/05/23
Albers Jeffrey W. Director Director Sep 27 Sell 49.86 25,000 1,246,500 176,050 09/29/23
Albers Jeffrey W. Director Director Sep 27 Option 1.87 25,000 46,750 182,948 09/29/23
Albers Jeffrey W. Director Director Aug 24 Sell 49.87 25,000 1,246,750 176,050 08/28/23
Albers Jeffrey W. Director Director Aug 24 Option 1.87 25,000 46,750 186,050 08/28/23
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jun 05 Sell 52.06 2,307 120,102 38,117 06/07/23
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Jun 05 Sell 52.05 1,404 73,078 36,878 06/07/23
Murray Christopher K. CHIEF TECHNICAL OPER.. CHIEF TECHNICAL OPERATIONS Mar 06 Sell 45.01 1,875 84,394 25,695 03/08/23
Rossi Christina CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Mar 06 Sell 45 3,059 137,655 55,376 03/08/23
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Mar 06 Sell 45.04 1,948 87,738 65,849 03/08/23
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Mar 06 Sell 45.25 1,514 68,508 38,282 03/08/23
Lee Philina CHIEF COMMERCIAL OFF.. CHIEF COMMERCIAL OFFICER Mar 06 Sell 45.06 1,676 75,521 31,178 03/08/23
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Mar 06 Sell 45.01 3,158 142,142 50,178 03/08/23
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Mar 06 Sell 45.25 761 34,435 40,424 03/08/23
Albers Jeffrey W. Director Director Mar 06 Sell 45 9,793 440,685 173,450 03/08/23
McCain Tracey L EVP AND CHIEF LEGAL.. EVP AND CHIEF LEGAL OFFICER Mar 06 Sell 45.07 3,322 149,723 52,666 03/08/23
Landsittel Michael CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Mar 06 Sell 45.1 3,007 135,616 48,523 03/08/23
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Mar 06 Sell 45.06 1,126 50,738 14,175 03/08/23
Haviland Kate CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Mar 06 Sell 45.19 6,640 300,062 125,641 03/08/23
Albers Jeffrey W. Director Director Dec 05 Option 8.44 20,000 168,800 203,243 12/07/22
Albers Jeffrey W. Director Director Dec 05 Sell 50.09 20,000 1,001,800 183,243 12/07/22
Namouni Fouad PRESIDENT, R & D PRESIDENT, R & D Oct 04 Sell 67.30 3,477 234,002 52,797 10/05/22
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Aug 24 Option 15.01 5,000 75,050 45,836 08/26/22
Durso-Bumpus Debra CHIEF PEOPLE OFFICER CHIEF PEOPLE OFFICER Aug 24 Sell 75.11 5,000 375,550 40,836 08/26/22
Albers Jeffrey W. Director Director Aug 19 Option 15.01 10,000 150,100 191,653 08/23/22
Albers Jeffrey W. Director Director Aug 19 Sell 70.6 10,000 706,000 183,243 08/23/22
Albers Jeffrey W. Director Director Aug 16 Option 8.44 20,000 168,800 203,243 08/18/22
Albers Jeffrey W. Director Director Aug 16 Sell 68.72 20,000 1,374,400 183,243 08/18/22
Albers Jeffrey W. Director Director Aug 08 Option 5.34 10,000 53,400 193,243 08/10/22
Albers Jeffrey W. Director Director Aug 08 Sell 70.07 10,000 700,700 183,243 08/10/22
Murray Christopher K. SVP, TECHNICAL OPERA.. SVP, TECHNICAL OPERATIONS Aug 04 Sell 62.72 5,000 313,600 18,820 08/08/22
Demetri George Director Director Jun 21 Buy 82.66 10 827 5,822 06/30/22
Demetri George Director Director Jun 21 Sell 58.56 10 586 5,812 06/30/22
Carter Percy H. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jun 06 Sell 59.76 1,908 114,022 28,685 06/08/22
Hewes L. Becker CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER Jun 06 Sell 59.88 4,375 261,975 27,296 06/08/22
Hurley Ariel PRINCIPAL ACCOUNTING.. PRINCIPAL ACCOUNTING OFFICER Mar 03 Sell 58.23 1,017 59,220 11,955 03/08/22